Evrópusambandið -
eistneska -
EMA (European Medicines Agency)
regkirona
celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - suguhormoonid ja immunoglobuliinid, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.
Eistland -
eistneska -
Ravimiamet
calcium/colecalciferol béres õhukese polümeerikattega tablett
beres pharmaceuticals ltd. - kaltsium+kolekaltsiferool - õhukese polümeerikattega tablett - 600mg+800rÜ 90tk; 600mg+800rÜ 120tk; 600mg+800rÜ 60tk; 600mg+800rÜ 30tk
Eistland -
eistneska -
Ravimiamet
calcivid 600 mg/400 iu õhukese polümeerikattega tablett
beres pharmaceuticals ltd. - kaltsium+kolekaltsiferool - õhukese polümeerikattega tablett - 600mg+400rÜ 90tk
Evrópusambandið -
eistneska -
EMA (European Medicines Agency)
masivet
ab science s.a. - masitinib mesilate - antineoplastilised ained - koerad - ravi mitte-resectable koer mast-rakkude kasvajad (klass 2 või 3), kellel on kinnitatud muteerunud c-kit türosiin-kinase retseptori.
Evrópusambandið -
eistneska -
EMA (European Medicines Agency)
mekinist
novartis europharm limited - trametiniib - melanoom - antineoplastilised ained - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ja 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. mitteväikerakk-kopsuvähk (mitteväikerakk-kopsuvähi)trametinib koos dabrafenib on näidustatud ravi täiskasvanud patsientidel, kaugelearenenud mitteväikerakk-kopsuvähi, mille braf v600 mutatsioon.